We recently published a list of 10 Stocks with Potential to Explode in 2025. In this article, we are going to take a look at ...

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

As we previously discussed, beginning in 2022, a series of patent infringement lawsuits were filed against Moderna and ...

Moderna (NASDAQ:MRNA – Get Free Report) had its price objective lowered by analysts at JPMorgan Chase & Co. from $40.00 to ...

Delving into the details, we found 40% of traders were bullish, while 50% showed bearish tendencies. Out of all the trades we ...

Shares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) have been assigned an average rating of “Hold” from the twenty-four ...

Shares of Moderna finished March 11 down by 93% from their peak in 2021. In addition to its COVID-19 vaccine, Moderna markets ...

Paula Newton speaks with co-founder and Chair of Moderna, Noubar Afeyan, about his hopes for the release of Ruben Vardanyan, ...

One of the most underappreciated applications of artificial intelligence in the corporate world involves its role in writing ...

U.S. health officials are reevaluating a $590 million contract that was awarded to Moderna for the development of its bird flu vaccine, Bloomberg News reported on Wednesday, citing sources.

Moderna recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent ...

As of 12:15:05 PM EDT. Market Open. Moderna stock skidded on reports Robert F. Kennedy Jr. is considering pulling funding for its bird flu vaccine. Is MRNA stock a sell? It's been nearly five ...